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BACKGROUND: Docetaxel plus cisplatin and 5-fluorouracil has become a new standard for treating advanced gastric cancer. However, high rates
of severe neutropenia limit its application. Modification of the regimen could be the solution to get similar activity but less myelosuppression.
METHODS: Patients with histologically confirmed, locally advanced, or recurrent/metastatic gastric adenocarcinoma without previous
chemotherapy were enrolled. This regimen consisted of docetaxel (Tyxan, TTY, Taipei, Taiwan) 30-min infusion at a dose of 36mgm
 2,
followed by cisplatin 30mgm
 2 infusion over 1h on days 1 and 8, ando r a lt e g a f u r / u r a c i l3 0 0m gm
 2 per day plus leucovorin 90mg per day
on days 1–14, every 3 weeks. Tumour response was evaluated after every 2 cycles of treatment.
RESULTS: From August 2007 to March 2009, 45 patients were enrolled. The median age was 56 years (range: 22–75). Among the 40 patients
evaluable for tumour response, one achieved a complete response, 22 had partial responses and 11 had stable disease. The overall response
rates of the evaluable and intent-to-treat (ITT) populations were 58% (95% CI: 41–74%) and 53% (95% CI: 38–68%), respectively.
The disease control rates in these populations were 85% (95% CI: 70–94%) and 82% (95% CI: 68–92%), respectively. In the ITT
analysis, the median time to progression and overall survival were 6.8 and 13.9 months, respectively. Major grade 3–4 toxicities were
neutropenia (51%), anaemia (22%), diarrhoea (16%), and infections (20%). No patient died of treatment-related toxicities.
CONCLUSION: Concurrent weekly docetaxel and cisplatin plus oral tegafur/uracil and leucovorin are effective and well tolerated in the
treatment of advanced gastric cancer.
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Gastric cancer is one of the leading causes of cancer death
worldwide (Roder, 2002). Although an early-stage disease can be
treated with curative resection, most patients show locally
advanced or metastatic disease on diagnosis. Furthermore,
recurrent tumours are observed in up to 50% of the patients
treated by curative intention using standardised surgical techni-
ques (McNeer et al, 1951; Dupont et al, 1978). The prognosis is
generally poor, with an overall 5-year survival of approximately
20% in most countries. The median survival time for patients who
presented with advanced or metastatic diseases and had the best
supportive care was only 3–5 months (Verdecchia et al, 2003).
With the introduction of novel drug administration schedules
and the emergence of new chemotherapeutic agents, modern
systemic chemotherapy can achieve 30–60% objective response
rates in advanced gastric cancers (Schoffski, 2002). However, the
overall survival (OS) remains consistently around 9–11 months, in
the expenditure of significant treatment-related toxicities (Ohtsu,
2005). New treatments with better therapeutic indexes are very
important for clinical management of these patients.
The non-overlapping toxicity profile of docetaxel, cisplatin, and
oral fluoropyrimidine, as well as the observations of schedule-
dependent synergism among docetaxel, cisplatin, and oral fluoro-
pyrimidine in human gastric carcinoma xenografts (Maeda et al,
2004; Kodera et al, 2005), warrants such a combination to be
evaluated in treating advanced gastric cancers. Recently, a
multicenter, open-label, randomised phase III trial (V325) was
conducted to evaluate the safety and efficacy of docetaxel for
treating patients with advanced gastric adenocarcinoma (Van
Cutsem et al, 2006). The patients were randomised to receive either
the investigational arm of the triplet combination of docetaxel,
cisplatin, and 5-fluorouracil (5-FU) (DCF), or the reference
standard regimen of cisplatin and 5-FU. Both overall response
rate (37 vs 25%) and time to progression (TTP) (5.6 vs 3.7 months)
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sfavored the DCF arm over the CF arm. The median OS was also
significantly longer for the DCF arm than the CF arm (9.2 vs 8.6
months). These findings represent an important milestone in the
treatment of patients with advanced gastric cancer and show that
DCF can become a new standard for treating advanced gastric
cancer. However, grade 3 or 4 neutropenia occurred in 82% of
patients on DCF, including 29% with complicated neutropenia.
The high rates of severe myelosuppression in the V325 study
could have been caused by (1) the 3-weekly regimen of docetaxel,
(2) high-dose cisplatin, and (3) 5-day continuous infusion of 5-FU.
To overcome the significant myelosuppression, weekly docetaxel
at a dose of 36mgm
 2 and cisplatin 30mgm
 2 was used to replace
the 3-weekly regimen, based on the previous reports that a
relatively lower dosage and a weekly regimen had similar efficacy
and better tolerability than the standard 3-weekly regimen
(Kunitoh et al, 1996; Hainsworth et al, 1998; Chen et al, 2002;
Schuette et al, 2005). Oral tegafur/uracil was used to replace the
5-days continuous infusion of 5-FU. This phase II study of
combination chemotherapy of weekly docetaxel, cisplatin, and oral
tegafur/uracil and leucovorin was conducted to determine if this
regimen could achieve activity similar to the original schedule in
the V325 study and be more tolerable for Asian patients with
advanced gastric adenocarcinoma.
PATIENTS AND METHODS
Study design and patients
This was a prospective, multi-center, phase II clinical trial of
docetaxel and cisplatin plus oral tegafur/uracil and leucovorin in
patients with advanced gastric cancer. The primary objective was
to determine the objective response rate in patients with advanced
gastric cancer. Secondary objectives included TTP, duration of
objective response, OS, and safety profiles.
Eligibility criteria of patients included (1) pathologically con-
firmed, locally advanced (unresectable), recurrent or metastatic gastric
adenocarcinoma, including gastroesophageal junction tumours;
(2) measurable disease by imaging studies; (3) no previous chemo-
therapy except for postoperative adjuvant chemotherapy received
more than 6 months before entry into the study; (4) ECOG
(Eastern Cooperative Oncology Group) performance status p2;
(5) age between 20 and 75 years; and (6) adequate hepatic, renal,
and bone marrow functions, including aspartate aminotransferase/
alanine aminotransferase p2.5 times the upper limit of normal)
(ULN) (p5.0 times the ULN if hepatic metastasis), alkaline
phosphatase p2.5 times the ULN (p5.0 times the ULN if bone
metastasis), total bilirubin p1.5 times the ULN, creatinine p1.0
times the ULN, haemoglobin X9g per 100ml, absolute neutrophil
count (ANC) X1500 per ml, and platelets X100000 per ml.
Exclusion criteria included (1) pre-existing peripheral neuro-
pathy; (2) pregnancy, breastfeeding, or woman of child-bearing
potential without adequate contraception; (3) concurrent or
previous malignancy; (4) central nervous system metastases;
(5) uncontrolled infection; (6) concurrent treatments that might
interfere with the study evaluation; and (7) inability to take the
study medication orally.
This study was approved by the ethics committees of all
participating institutes and signed informed consent was obtained
from all patients.
Chemotherapy protocol
Docetaxel (Tyxan, TTY Biopharm, Taipei, Taiwan) 30-min
infusion at a dose of 36mgm
 2, followed by cisplatin 30mgm
 2
infusion over 1h on days 1 and 8, and oral tegafur/uracil (UFUR)
300mgm
 2 per day plus leucovorin (Folina) 90mg per day on
days 1–14, every 21 days, was administered. To reduce the risk of
hypersensitivity reactions to docetaxel, all patients were pre-
medicated with oral dexamethasone 8mg twice daily for 3 days
starting 1 day before docetaxel, or intravenous dexamethasone
10mg 30min before receiving docetaxel.
The total dose of cisplatin was dissolved in 250ml of sterile
saline and infused over a 1-hour period. Pretreatment hydration
with 1–2l of fluids infused before cisplatin dose was recom-
mended. The total daily dose of tegafur/uracil was determined and
rounded to the nearest 100mg and divided into three doses given
8h apart. If the total number of tablets could not be evenly divided,
the highest dose was given in the morning and the lower doses in
the afternoon or evening. Cycles were repeated every 3 weeks or on
recovery from toxicities to baseline or grade 1 (except for alopecia
and anaemia).
Dose modification
Dose modifications were based on haematologic and non-
haematologic toxicities. Haematology test was performed every
week to monitor haematologic recovery. Chemotherapy doses were
reduced or treatment was delayed for no more than 2 weeks to
allow patients to recover from toxicities. The dose of each study
drug was reduced stepwise. Level-1 was docetaxel 30mgm
 2,
cisplatin 25mgm
 2, tegafur/uracil 200mgm
 2, and leucovorin
90mg per day. Level-2 was docetaxel 25mgm
 2 and cisplatin
20mgm
 2, whereas tegafur/uracil and leucovorin were withdrawn.
A maximum of two dose level reductions were allowed per patient
and any patient who required more was excluded from the
treatment protocol.
If a haematology test within 72h before the next cycle indicated
a neutrophil count o1500 per mm
3 or a platelet count o100000
per mm
3, the next cycle was delayed until haematologic recovery.
At haematologic nadir, if the neutrophil count was o1000mm
3 or
platelets was o50000mm
3, the next dose was reduced by one level
on day 1 of a new cycle. If the neutrophil count was o1000mm
3 or
the platelet count was o50000mm
3 on day 8 within a cycle, the
chemotherapy was omitted. The prophylactic use of recombinant
granulocyte colony-stimulating factor (G-CSF) was not permitted.
However, if a patient develops grade 4 neutropenia (ANC o500 per
mm
3), the use of recombinant G-CSF was allowed for subsequent
cycles.
Chemotherapy administration was resumed at the same dose
level during the cycle on recovery from non-haematologic
toxicities to the baseline or grade 1 (except for alopecia and
anaemia). If such recovery was not achieved before day 8 from the
scheduled date, the chemotherapy dose was skipped on day 8. The
next dose was reduced by one level. If a patient developed grade 1
or 2 nephrotoxicity (creatinine 1.0–3.0 times the ULN), cisplatin
was omitted, and then reduced one dose level in the next dose on
recovery to grade 1. If more than two reductions of dose level were
needed, the patient was withdrawn from the study. If grade 3 or 4
nephrotoxicity (43.0 times the ULN) occurred, the patient was
withdrawn from the study. If diarrhoea greater than grade 2
occurred, tegafur/uracil and leucovorin were reduced one dose
level plus the patient was given appropriate treatment for
diarrhoea. If it reappeared, then the patient was withdrawn from
the study. When toxicity subsided to baseline or less than grade 1,
administration was resumed. Therapy was withheld until recovery
for a maximum of 2 weeks; otherwise, the patient was withdrawn
from the study. Treatment was not continued after treatment cycle
day 14 regardless of the number of days the drug was interrupted.
Treatment was administered until disease progression, intolerable
toxicity, or consent withdrawal.
Evaluation of efficacy and toxicities
Evaluations before chemotherapy included obtaining patient’s
medical history, physical examination, complete blood count,
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graphy (CT). After starting the protocol treatment, complete
blood count was examined weekly and blood chemistry every
3 weeks. Detailed medical history, physical examinations, and
treatment-related toxicities were recorded weekly. Tumour size
was measured by imaging studies every 6 weeks. Tumour response
was evaluated according to the Response Evaluation Criteria
in Solid Tumors (RECIST) criteria (Therasse et al, 2000). All
patients with tumour responses (complete or partial response)
received a confirmatory scan 4 weeks following the initial
documentation.
Toxicities were graded, from the time of study entry through
30 days after the last dose of study medication was administered,
according to the National Cancer Institute-Common Terminology
Criteria for Adverse Events (v3.0) (Trotti et al, 2003).
Statistical methods
The treatment programme was designed to reject a response rate of
o25% (P0) and to provide a statistical power of 0.80 in assessing
the activity of the regimen as 50% (P1) with an a-error of 0.05. A
total of 37 patients were therefore required. Time to progression
was defined as the duration from the date of starting protocol
treatment to the date of disease progression. Data of patients who
were lost to follow-up before progression were censored at the date
of their last CT scan. Overall survival represented the duration
from the date of starting protocol treatment to the date of death
from any cause. Survival was estimated by the Kaplan–Meier
analysis. All statistics were two-sided and performed using SAS
software (version 9.1.3, SAS Inc., Cary, NC, USA).
RESULTS
Patients and treatment
Between August 2007 and March 2009, 45 patients from five
medical centres were enrolled in the study. Their clinicopathological
characteristics are listed in Table 1. A total of 271 (median: 6;
range: 1–21) cycles of chemotherapy were given. The median
relative dose intensity was 82% (range: 46–100%) for docetaxel,
80% (range: 46–100%) for cisplatin, 95% (range: 54–100%) for
tegafur/uracil, and 95% (range: 54–100%) for leucovorin. In total,
62% of the patients received more than 80% of the intended doses
of docetaxel, 53% received more than 80% of the intended doses of
cisplatin, and 89% received more than 80% of the intended doses
of tegafur/uracil and leucovorin.
Efficacy
Five patients were not evaluable for responses: three failed to
return for tumour measurements, one was later found to have
protocol violation, and one refused further chemotherapy after one
treatment cycle. Among the 40 evaluable patients, the best tumour
response was complete response in 1, partial response (PR) in 22,
stable disease in 11, and progressive disease in 6. The overall
response rates of the evaluable and intent-to-treat (ITT) popula-
tions were 58% (95% CI: 41–74%) and 53% (95% CI: 38–68%),
respectively, whereas the disease control rate in according
population was 85% (95% CI: 70–94%) and 82% (95% CI:
68–92%), respectively. The response rates of patients with X80
and o80% of the scheduled docetaxel dose intensity were 58%
(19 out of 33) and 57% (4 out of 7), respectively (P¼1.0000). The
response rates of patients with X80 and o80% of scheduled
cisplatin dose intensity were 62% (18 out of 29) and 45% (5 out of
11), respectively (P¼0.7665). The response rates of patients with
X80 and o80% of scheduled tegafur/uracil dose intensity were
57% (20 out of 35) and 60% (3 out of 5), respectively (P¼1.0000).
Median time to tumour response was 1.8 (range: 1.2–6.4) months.
Median duration of tumour response was 5.5 (range: 2.4–14.9)
months. Of the 45 patients, 28 received second-line therapies.
Among them, 19 patients received cisplatin plus 5-FU and
leucovorin, 4 patients received oxaliplatin plus 5-FU and
leucovorin, 1 patient received oxaliplatin plus tegafur/uracil
and leucovorin, 1 patient received 5-FU and leucovorin, 1 patient
received oxaliplatin and capecitabine, 1 patient received cisplatin
plus 5-FU, leucovorin, and cetuximab, and 1 patient received
everolimus.
Median follow-up time was 13.3 (range: 1.7–27.8) months.
Median TTP and OS were 6.8 (95% CI: 2.3–11.3) months and 13.9
(95% CI: 10.7–17.2) months, respectively. The Kaplan–Meier
estimated TTP and OS curves are shown in Figures 1 and 2,
respectively. The fraction of patients alive at 1 year was 60% and
at 2 years was 7%.
Table 1 Clinicopathologic features of the patients
Patient number (%)
Total patients 45
Age (years), median (range) 56 (22–75)
Sex: male/female 27/18
ECOG performance
0 20 (44)
1 23 (51)
2 2 (4)
Treatments for primary tumour
No previous therapy 9 (20)
Surgery only 27 (60)
Surgery+adjuvant chemotherapy 7 (16)
Radiotherapy 2 (4)
Disease status
Locally advanced 4 (9)
Recurrence/metastasis 41 (91)
Disease sites
Liver 9 (20)
Lymph nodes 34 (76)
Peritoneum 1 (2)
Gastrointestinal tract 25 (56)
Bone 2 (4)
Lung 0 (0)
Others 24 (53)
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Figure 1 Time to progression of the 45 patients.
Weekly docetaxel, cisplatin, UFUR, and leucovorin in gastric cancer
C-P Li et al
1345
British Journal of Cancer (2010) 103(9), 1343–1348 & 2010 Cancer Research UK
C
l
i
n
i
c
a
l
S
t
u
d
i
e
sToxicity
All patients were evaluated for toxicities (Table 2). The most
common toxicity was neutropenia, with grades 3–4 neutropenia
observed in 51% of the patients. Two patients developed
neutropenic fever and recovered with appropriate therapy. Grade
3 anaemia was observed in 22% of the patients. Grades 3–4
diarrhoea developed in seven patients (16%). Grade 3 infections
occurred in nine patients (20%), with one device-related infection,
one nail infection, one wound infection, one urinary tract
infection, and five pneumonia. A total of 36 (80%) patients had
dose delays during treatment. Dose modification to level-1 was
required in 19 (42%) patients, whereas level-2 dose modification
was required in two patients (4%). Treatment-related toxicity
resulted in treatment discontinuation in eight (18%) patients,
which were associated with neutropenia in two, thrombocytopenia
in two, pneumonia in two, anaemia in one and serum creatinine
increased in one. There was no treatment-related mortality.
DISCUSSION
The V325 study showed that docetaxel in combination with
cisplatin and 5-FU (DCF) could become a new standard therapy for
the treatment of advanced gastric cancer (Van Cutsem et al, 2006).
However, grade 3 or 4 neutropenia occurred in 82% of patients on
DCF. The high incidence of neutropenia becomes a critical issue
for clinical application of the DCF regimen. Recently, the superior
therapeutic index of weekly docetaxel over the 3-weekly schedule
has been demonstrated in gastric cancer patients (Ajani et al, 2005;
Evans et al, 2007b; Roth et al, 2007; Wang et al, 2009). With
comparable tumour response rates (37–48%) for advanced gastric
cancer, grades 3–4 neutropenia of weekly docetaxel (33.3mgm
 2,
on days 1, 8, and 15 every 4 weeks or 40mgm
 2, on day 1 and 8
every 3 weeks) was less common than that of 3-weekly docetaxel
(75–85mgm
 2, on day 1 every 3 weeks) (o10–48 vs 57–86%).
Weekly docetaxel and platinum plus either infusional 5-FU or oral
fluoropyrimidine have become popular investigational combina-
tions for advanced gastric cancers (Chen et al, 2002; Evans et al,
2007a,b; Wang et al, 2009).
This is the first phase II study investigating weekly docetaxel
and platinum plus oral fluoropyrimidine in treating advanced
gastric cancer. The 58% overall response rate of the evaluable
patients (53% on ITT analyses), median survival of 13.9 months
and grades 3–4 neutropenia in 51% of participants are not inferior
to the results of other phase II clinical trials with topoisomerase I
inhibitor-, taxane-, or third-generation oral fluoropyrimidine-
based (i.e., S-1 and capecitabine) doublet chemotherapy regimens
(Schoffski, 2002; Ohtsu, 2005), in which the objective tumour
response rate and median survival ranged from 40 to 76% and
from 9 to 12.5 months, respectively. The median survival in this
study was also comparable with those achieved in previous high-
dose 5-FU and leucovorin-based studies in Taiwan (Hsu et al,
1997; Chen et al, 2002; Chao et al, 2004, 2006), and to the 6.1–12.0
months median survival of phase II or III studies of current
‘reference’ regimens for advanced gastric cancers, that is, ECF,
FAMTX, ELF, FUP, FOLFOX-6, and DCF (Webb et al, 1997;
Vanhoefer et al, 2000; De Vivo et al, 2000; Louvet et al, 2002;
Ohtsu, 2005; Van Cutsem et al, 2006).
The overall response rates of evaluable and ITT populations
were 58 and 53% in this study. Among other docetaxel-based
studies, the tumour response rate ranged from 37 to 43% in
chemo-naive gastric cancer patients (Ajani et al, 2005; Van Cutsem
et al, 2006; Roth et al, 2007). The OS of 13.9 months, TTP of 6.8
months, and toxicity profiles (51% grades 3–4 neutropenia) of the
current regimen are also comparable with those observed in
previous docetaxel-based trials (OS 9.2–10.4 months, TTP 4.6–5.9
months, and 57–86% grades 3–4 neutropenia) (Ajani et al, 2005;
Van Cutsem et al, 2006; Roth et al, 2007). Although this regimen
was less toxic than other previously described combination
therapies, the incidence of grade 4 neutropenia (18%) and
treatment discontinuation due to treatment-related toxicity
(18%) was still high. Further modification of the dosage of this
regimen or addition of prophylactic G-CSF should be considered
in the management of these patients. On the other hand, 76% of
our patients had undergone gastrectomy previously, and the
incidence of liver metastasis (20%) or peritoneal seeding (2%) was
relatively low compared with that in other studies. A large
proportion of recurrent disease and low tumour burden could have
contributed to the good response rate and survival results in this
study (Lee et al, 2007).
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Figure 2 Overall survival of the 45 patients.
Table 2 Percentages of toxicity of the docetaxel, cisplatin, tegafur/uracil,
and leucovorin regimen
Patients (n¼45) Cycles (n¼271)
Grade Grade Grade Grade
Toxicity 1 2 3 4 1 2 3 4
Haematological
Neutropenia 4
a 11 33 18 11
b 13 17 6
Leukopenia 7 31 24 9 17 16 10 1
Thrombocytopenia 18 9 2 2 21 2 0.4 0.4
Febrile neutropenia
c 00 4 0 0 0 1 0
Anaemia 2 58 22 0 4 27 5 0
Gastrointestinal
Nausea 31 22 7 0 19 6 1 0
Vomiting 22 29 4 0 12 7 1 0
Diarrhoea 22 33 13 2 16 14 3 0
Stomatitis 13 22 7 0 5 11 4 0
Anorexia 24 24 4 0 18 6 8 0
Weight loss 20 16 2 0 10 6 0.4 0
Neurosensory 7 2 0 0 10 1 0 0
Others
Hand and foot syndrome 4 4 0 0 3 5 0 0
Fever 16 7 0 0 6 1 0 0
Infections 11 16 20 0 5 5 7 0
Alopecia 36 9 0 0 31 5 0 0
aAll numbers are percentages of the 45 patients.
bAll numbers are percentages of the
271 cycles given.
cFebrile neutropenia was defined as fever of unknown origin without
clinically or microbiologically documented infection with absolute neutrophil count
o1.0 10
9/l and fever X38.51C, according to the National Cancer Institute
Common Terminology Criteria for Adverse Events 3.0.
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of the requirement and cost of central venous catheter implanta-
tion and the inconvenience of an infusion pump, which in turn
may improve the quality of life of treated patients. In this study, we
used tegafur/uracil replacing infusional 5-FU. Both tegafur/uracil
and capecitabine are commonly used oral fluoropyrimidines and
have similar antitumor activities (Twelves et al, 2005; Lembersky
et al, 2006). Capecitabine has a higher rate of grades 3 and 4 hand
foot syndrome, whereas tegafur/uracil has a higher rate of grades 3
and 4 diarrhoea (Twelves et al, 2005; Lembersky et al, 2006). This
is consistent with our findings of no grades 3 and 4 hand foot
syndrome, but occurrence of grade 3 diarrhoea in 13% of our
patients.
Orditura et al (2006) reported that weekly docetaxel and
capecitabine is not effective in the treatment of advanced gastric
cancer. In that study, the dose of docetaxel was similar to that of
our current study, whereas the dose of capecitabine was relatively
low at 625mgm
 2 twice daily per os on days 5–18 repeated every
4 weeks, which may be inadequate for gastric cancer. Despite a low
rate of myelosuppression, diarrhoea, and hand foot syndrome, the
response rate was only 21%. In our study, the higher response rate
could be due to adequate tegafur/uracil dosage (300mgm
 2 per
day as recommended for gastric cancer). Moreover, there was a
synergistic effect among cisplatin, tegafur/uracil, and docetaxel
(Maeda et al, 2004; Kodera et al, 2005).
Recently, several novel targeted therapeutic agents such as
inhibitors of epidermal growth factor receptor or of vascular
endothelial growth factor, when in combination with chemo-
therapy, have shown promising activity against gastrointestinal
cancers (Chong and Cunningham, 2005). The low-toxicity profiles
of such agents also provide an excellent chance to improve the
therapeutic index of this active and convenient regimen for
advanced gastric cancer patients.
In conclusion, the combination of weekly docetaxel, cisplatin
and oral tegafur/uracil, and leucovorin is an active, outpatient-
based chemotherapy regimen with acceptable toxicities. Strategies
to improve the therapeutic index of the current regimen, such as
administration in combination with novel biological-targeted
agents, should be further explored.
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